New surgical approaches for clinically high-risk or metastatic prostate cancer

A considerable number of individuals with prostate cancer (PCa) still harbor locally-advanced and metastatic disease. Although such men were initially not considered eligible for local treatment, the role of radical prostatectomy (RP) has been recently reassessed. Areas covered: This review analyses currently published evidences regarding new surgical approaches for clinically high-risk PCa individuals, as well as the role of cytoreductive surgery in the metastatic setting. The role of robot-assisted radical prostatectomy (RARP) and extended pelvic lymph node dissection will be evaluated with regards to perioperative, oncologic, as well as functional outcomes. Expert commentary: RARP is a feasible approach in PCa patients regardless of the presence of high-risk disease features and can achieve optimal short-term oncologic outcomes and acceptable short/intermediate-term functional outcomes, that are comparable to those reported for open RP. Extended pelvic lymph node dissection can be performed in this setting and should be recommended for all high-risk PCa patients. The overall rate of complications in contemporary men treated with RARP for high-risk disease is not negligible. Cytoreduction in the oligo-metastatic setting is feasible and relatively safe, although evidence is scarce to recommend its widespread adoption. In consequence, longer follow-up data and, ideally, randomized controlled trials are needed.

Expert review of anticancer therapy. 2017 Sep 01 [Epub ahead of print]

Paolo Dell'Oglio, Armando Stabile, Giorgio Gandaglia, Emanuele Zaffuto, Nicola Fossati, Marco Bandini, Nazareno Suardi, Pierre I Karakiewicz, Shahrokh F Shariat, Francesco Montorsi, Alberto Briganti

a Department of Urology and Division of Experimental Oncology , URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute , Milan , Italy., b Cancer Prognostics and Health Outcomes Unit , University of Montreal Health Center , Montreal , Canada., c Department of Urology , Medical University of Vienna and General Hospital , Vienna , Austria .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe